Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Total Long-Term Assets: €559.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ROVI Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
89 GF Score
Price €59.25
GF Value €54.48
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Total Long-Term Assets?

Laboratorios Farmaceuticos Rovi XMAD:ROVI -0.50% 89 Total Long-Term Assets is €559.1 Mil as of Jun. 2026. GuruFocus rates XMAD:ROVI with a GF Score™ of 89/100 and a GF Value™ of €54.48 (Fairly Valued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Laboratorios Farmaceuticos Rovi's Total Long-Term Assets for the quarter that ended in Jun. 2026 was €559.1 Mil.

Laboratorios Farmaceuticos Rovi Total Long-Term Assets Related Terms

Laboratorios Farmaceuticos Rovi Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Total Long-Term Assets Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 226.31 255.63 290.55 342.42 388.98

Laboratorios Farmaceuticos Rovi Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 353.30 362.88 388.98 387.04 559.07
XMAD:ROVI
89GF Score
Laboratorios Farmaceuticos Rovi SA XMAD:ROVI
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €559.1 Mil mean?
Laboratorios Farmaceuticos Rovi (XMAD:ROVI) has a Total Long-Term Assets of €559.1 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Total Long-Term Assets too high?
Laboratorios Farmaceuticos Rovi's current Total Long-Term Assets is €559.1 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Total Long-Term Assets compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Total Long-Term Assets of €559.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Total Long-Term Assets is €559.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (XMAD:ROVI) is currently considered Fairly Valued. The stock's GF Value™ is €54.48, compared to a current price of €59.25 — trading 8.8% above its estimated fair value. The current Total Long-Term Assets is €559.1 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (XMAD:ROVI), the current Total Long-Term Assets is €559.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €59.25 is trading 8.8% above its estimated GF Value™ of €54.48. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.

Key valuation signals for XMAD:ROVI:

  • Total Long-Term Assets: €559.1 Mil
  • GF Value™: €54.48 vs. price of €59.25 (8.8% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the XMAD:ROVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score

Get the complete analysis for XMAD:ROVI

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€59.25
Price
€54.48
GF Value